NYSEAMERICAN:CANF - CAN-FITE BIOPHA/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.37 +0.03 (+2.24 %)
(As of 11/15/2018 04:00 PM ET)
Previous Close$1.37
Today's Range$1.31 - $1.40
52-Week Range$1.12 - $2.75
Volume38,400 shs
Average Volume150,105 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CANF
Previous Symbol
CUSIPN/A
Phone+972-3-9241114

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees7
Outstanding Shares19,980,000
Market Cap$0.00
OptionableOptionable

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) Frequently Asked Questions

What is CAN-FITE BIOPHA/S's stock symbol?

CAN-FITE BIOPHA/S trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How were CAN-FITE BIOPHA/S's earnings last quarter?

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) issued its quarterly earnings data on Friday, August, 31st. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. The biotechnology company earned $0.27 million during the quarter, compared to analyst estimates of $2 million. View CAN-FITE BIOPHA/S's Earnings History.

When is CAN-FITE BIOPHA/S's next earnings date?

CAN-FITE BIOPHA/S is scheduled to release their next quarterly earnings announcement on Monday, November 26th 2018. View Earnings Estimates for CAN-FITE BIOPHA/S.

What price target have analysts set for CANF?

2 equities research analysts have issued 1-year price targets for CAN-FITE BIOPHA/S's stock. Their predictions range from $7.00 to $8.00. On average, they expect CAN-FITE BIOPHA/S's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 447.4% from the stock's current price. View Analyst Price Targets for CAN-FITE BIOPHA/S.

What is the consensus analysts' recommendation for CAN-FITE BIOPHA/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CAN-FITE BIOPHA/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CAN-FITE BIOPHA/S.

What are Wall Street analysts saying about CAN-FITE BIOPHA/S stock?

Here are some recent quotes from research analysts about CAN-FITE BIOPHA/S stock:
  • 1. HC Wainwright analysts commented, "We also note that Namodenoson has both Track status in the hepatocellular carcinoma (HCC) indication. Namodenoson could be approved based on this study. The trial is a Phase 2 study, but given the unmet medical need, if the data is strong enough, it could be used as a registrational study. For this reason and for ethical reasons, management has been advised not to alter the original study design (statistical plan)." (10/31/2018)
  • 2. Maxim Group analysts commented, "While we anticipated CanFite would need to raise capital we did not anticipate the added dilution announced in today’s raise and the potential impact of raising too little capital which sets up additional dilution." (3/9/2018)

Has CAN-FITE BIOPHA/S been receiving favorable news coverage?

Press coverage about CANF stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CAN-FITE BIOPHA/S earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.

Are investors shorting CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 356,891 shares, an increase of 11.7% from the October 15th total of 319,636 shares. Based on an average trading volume of 63,322 shares, the days-to-cover ratio is presently 5.6 days. View CAN-FITE BIOPHA/S's Current Options Chain.

Who are some of CAN-FITE BIOPHA/S's key competitors?

Who are CAN-FITE BIOPHA/S's key executives?

CAN-FITE BIOPHA/S's management team includes the folowing people:
  • Dr. Ilan Cohn, Co-Founder & Chairman (Age 64)
  • Prof. Pnina Fishman, Scientific Founder, Chief Exec. Officer & Director (Age 70)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 54)
  • Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 46)
  • Dr. Michael H. Silverman M.D., F.A.C.P.,FACR, Medical Director

How do I buy shares of CAN-FITE BIOPHA/S?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CAN-FITE BIOPHA/S's stock price today?

One share of CANF stock can currently be purchased for approximately $1.37.

What is CAN-FITE BIOPHA/S's official website?

The official website for CAN-FITE BIOPHA/S is http://www.canfite.co.il.

How can I contact CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114.


MarketBeat Community Rating for CAN-FITE BIOPHA/S (NYSEAMERICAN CANF)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  207
MarketBeat's community ratings are surveys of what our community members think about CAN-FITE BIOPHA/S and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by MarketBeat.com Staff

Featured Article: Bear Market

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel